TOPICS: Neuromuscular blocking drugs, succinylcholine, nicotinic acetylcholine receptor agonist, sustains depolarisation at neuromuscular end plate, muscle contraction, inactivate sodium channels, no antidote for phase I, prolonged depolarisation phase, phase II, repolarization, flaccid paralysis, cholinesterase inhibitors can reverse phase II blockade, hypercalcaemia, hyperkalemia, malignant hyperthermia, pseudocholinesterase deficiency, prolonged paralysis, prolonged apnea, upregulation of muscle nicotinic ACh receptors, acute hyperkalemia, crush injuries, burn injuries, myopathies, denervating injuries, quadriplegia, Guillain Barre syndrome, rhabdomyolysis, non depolarizing neuromuscular junction drugs, competitive ACh antagonists, atracurium, rocuronium, tubocurarine, AChE inhibitors, neostigmine, edrophonium, bradycardia, atropine, glycopyrrolate
